Enjoy complimentary customisation on priority with our Enterprise License!
Report on How AI is Driving Market Transformation 
The menstrual drugs market size is forecast to increase by USD 3.62 billion at a CAGR of 7.75% between 2023 and 2028. The market is experiencing significant growth due to several key factors. Firstly, there is a growing awareness and emphasis on menstrual hygiene and overall women's health, leading to an increase in demand for menstrual cramp treatments. Secondly, drug therapy, particularly prostaglandins, non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen sodium, remain popular options for managing menstrual cramps. Additionally, hormonal therapy is also gaining traction as an alternative treatment. As Menstrual Hygiene Day continues to raise awareness about menstrual health, the market for menstrual drugs is expected to continue its expansion. Lastly, non-drug alternatives, including herbal remedies and menstrual cups, are gaining popularity as more women seek natural and eco-friendly options. Overall, the market is poised for continued growth as more women seek effective solutions for managing menstrual cramps and maintaining their overall health.
The market encompasses various treatments for menstrual cramps and related conditions such as primary dysmenorrhea and secondary dysmenorrhea. These conditions, characterized by pelvic pain and discomfort during menstruation, can significantly impact a woman's quality of life. The treatment market for menstrual cramps consists of several types, including medication, therapy, and surgery. Medications are the most common form of treatment and can be administered orally, topically, or injectable. Prostaglandins, a type of hormone-like substance, are often used to treat primary dysmenorrhea. Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen sodium are popular over-the-counter options for relieving menstrual cramps.
Furthermore, hormonal therapy is another treatment type for menstrual cramps, particularly for those with secondary dysmenorrhea or endometriosis. This therapy aims to regulate hormonal imbalances and reduce pelvic pain. Clinical trials for new hormonal therapies are currently in phase 2, indicating ongoing research and development in this area. Diagnosis of menstrual cramps and related conditions involves various methods, including ultrasound, laparoscopy, and CT scan. These diagnostic tools help healthcare professionals identify the underlying causes of pelvic pain and determine the most effective treatment approach. The duration of menstrual cramp treatment varies depending on the individual's response to therapy and the severity of their symptoms.
For some, over-the-counter medications may be sufficient, while others may require prescription medications or even surgery. In terms of administration, medications for menstrual cramps can be taken orally, applied topically, or administered via injection. Oral administration is the most common method, as it allows for easy and convenient dosing. Topical administration, such as heating pads or hot water bottles, can also provide relief for some women. The market is expected to grow due to increasing awareness of menstrual health and the availability of effective treatment options. Additionally, advancements in diagnostic tools and treatment methods are driving innovation in the market.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The hormonal treatments segment is estimated to witness significant growth during the forecast period. The hormonal treatments segment in the market caters to various menstrual conditions by addressing hormonal imbalances and regulating menstrual cycles. This segment comprises a multitude of pharmaceutical interventions, such as hormonal contraceptives, hormone replacement therapies, and other hormonal medications. The rising incidence of menstrual disorders and the escalating demand for efficient hormonal management solutions have amplified the importance of the hormonal treatments segment in The market. One of the primary factors fueling the expansion of the hormonal treatments segment is the extensive application of hormonal contraceptives for birth control and menstrual cycle regulation. These treatments are administered through various modes, including oral, parenteral, implants, and prescription or over-the-counter options.
Furthermore, advanced diagnostic techniques, such as laparoscopy and CT scans, are increasingly being used to determine the underlying causes of menstrual disorders, thereby driving the need for hormonal treatments. The market is expected to grow significantly due to the increasing awareness and acceptance of hormonal treatments for managing menstrual disorders.
Get a glance at the market share of various segments Request Free Sample
The hormonal treatments segment accounted for USD 1.45 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is expected to expand due to the presence of prominent healthcare companies offering effective female healthcare medications through hospitals and clinics. In 2023, the US was the leading contributor to the market's revenue, attributed to the rising prevalence of infertility and related disorders among women. For instance, the Centers for Disease Control and Prevention (CDC) reported that 13% of married women in the US, aged 15-44 years, experienced infertility in 2022. Furthermore, the Public Health Agency of Canada estimated that one in six Canadian couples encounter infertility, and about forty percent of women deal with fertility issues annually.
Further, heavy Menstrual Bleeding (HMB) is a common disorder among women, leading to an increased demand for menstrual drugs. Treatment for HMB includes various administration methods such as oral, injectable, and topical. In Clinical Trial Phase 2, new drugs are being developed to address the challenges associated with current treatments. For pain relief, analgesics are often used, and these medications can be administered orally or injected. Topical administration is also an option for certain treatments. The market for menstrual drugs in North America is anticipated to grow significantly due to the increasing demand for effective treatments for HMB and associated disorders.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Growing emphasis on educating women about menstrual health is the key driver of the market. The market has experienced significant growth due to increasing awareness and education surrounding menstrual health. This shift in focus empowers women to make informed decisions regarding their reproductive health and understand various menstrual disorders. Early detection and diagnosis of menstrual disorders are key benefits of this educational movement. Hospital pharmacies, retail pharmacies, and online pharmacies are all impacted by this trend, as women seek out appropriate treatments for their menstrual needs.
Advancements in technology, offer alternative treatment options for menstrual cramps and pain. Medical reimbursement policies are also evolving to cover menstrual health-related expenses, further increasing accessibility to these treatments. Menstrual hygiene remains a priority, with various organizations and publications providing resources and information to promote good menstrual health practices. Overall, the market is poised for continued growth as women become more informed and proactive about their menstrual health.
Increase in popularity of drug therapy is the upcoming trend in the market. The market has witnessed significant growth due to the introduction of over-the-counter medicines and online providers. Pharmaceutical companies and research institutions have been investing in the development of new drug formulations and treatment modalities to address menstrual-related conditions.
This has led to the availability of innovative drug therapies with enhanced efficacy, safety, and patient convenience, thereby increasing their adoption for managing menstrual health. Drug stores continue to be a significant distribution channel for menstrual drugs, while online providers offer added convenience and accessibility.
Increasing popularity of non-drug alternatives is a key challenge affecting the market growth. The Menstrual Hygiene Day highlights the importance of addressing menstrual health and the various treatments available in the market. While prostaglandins, non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen and Naproxen sodium, and hormonal therapy remain popular options for managing menstrual cramps, there has been a notable shift towards non-drug alternatives. The rise of natural remedies and holistic approaches to health and wellness has led to an increase in the use of herbal supplements, dietary changes, exercise, acupuncture, yoga, and mindfulness practices for managing menstrual symptoms. These alternatives offer individuals a more natural and potentially safer solution compared to conventional medications.
However, the market still holds significance, particularly for those experiencing severe menstrual cramps or other menstrual-related conditions. It is essential to consider both traditional and alternative treatments when addressing menstrual health concerns and making informed decisions based on individual needs and preferences. In conclusion, while the market continues to serve a vital role in managing menstrual symptoms, the growing trend towards natural and holistic approaches to health and wellness has led to a decline in demand for conventional medications. It is crucial to explore all available options and consult healthcare professionals for personalized recommendations.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers menstrual drug namely elagolix to manage moderate to severe pain associated with endometriosis.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market encompasses various treatments and therapies aimed at alleviating symptoms associated with menstruation, including primary and secondary dysmenorrhea. These conditions cause pelvic pain and heavy menstrual bleeding, impacting millions of women worldwide. Treatment options range from medication, therapy, and surgery. Medications include analgesics like ibuprofen and naproxen sodium, available over the counter or through prescription, administered orally or parenterally. Hormonal therapy, such as combined oral contraceptives, is also a common treatment. Diagnostic procedures like ultrasound, laparoscopy, and CT scan help in diagnosis. Hospital pharmacies, retail pharmacies, and online pharmacies distribute these medications. Alternative treatments, such as Livia portable device using Smartwave technology, are gaining popularity.
Further. medical reimbursement and menstrual hygiene initiatives, including Menstrual Hygiene Day, are essential aspects of this market. The pipeline analysis includes gene therapy, Digital Health, and telemedicine, aiming to improve treatment duration and patient experience. Side effects and healthcare infrastructure are crucial considerations in the market. Endometriosis and heavy menstrual bleeding are significant conditions addressed by this market. Clinical trials in phase 2 explore new treatment possibilities.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
220 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 7.75% |
|
Market growth 2024-2028 |
USD 3.62 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
7.31 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 33% |
|
Key countries |
US, China, Germany, India, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Adorefem, Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Haleon Plc, Himalaya Wellness Co., Johnson and Johnson Services Inc., Leeford Healthcare Ltd., Mallinckrodt Plc, Maxwellia Ltd., Perrigo Co. Plc, Pfizer Inc., Reckitt Benckiser Group Plc, Sanofi SA, SteriMax Inc., Sumitomo Chemical Co. Ltd., Teva Pharmaceutical Industries Ltd., Walgreens Boots Alliance Inc., and Zydus Lifesciences Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Route of Administration
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
With the growing adoption of AI across industries, Technavio has analyzed its impact on global menstrual drugs market significant advancements in 2024, driven by the integration of Artificial Intelligence (AI). AI is playing a transformative role in enhancing drug development, optimizing supply chain management, personalizing patient care, and improving market analytics. This analysis delves into AI's impact on the Menstrual Drugs market, backed by data and real-world examples.
These insights, available exclusively through Technavio, provide an unparalleled significant impact of AI on the Menstrual Drugs market, backed by real-world examples and data.
The report provides details of AI's impact on various segment
Learn more about how AI is transforming Menstrual Drugs Market - Buy Full Report Now
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
